Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 5.9% - Still a Buy?

Key Points

• AVTX shares rose 5.9% to $20.90 in mid-day trading, although volume was 64% below the average daily level. The stock trades above its 50-day and 200-day moving averages.
• Analyst sentiment remains broadly positive: 13 analysts rate Avalo Therapeutics a Buy and one rates it a Sell, producing a “Moderate Buy” consensus and an average price target of $45.10.
• The company reported a quarterly loss of $0.83 per share, missing the $0.58 consensus estimate, and analysts expect a full-year loss of $2.59 per share. Avalo is a clinical-stage biotechnology company developing therapies for cardiometabolic, fibrotic and inflammatory diseases.

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) rose 5.9% during mid-day trading on Wednesday . The company traded as high as $20.93 and last traded at $20.90. 411,364 shares traded hands during trading, a decline of 64% from the average daily volume of 1,156,686 shares. The stock had previously closed at $19.74.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AVTX. HC Wainwright cut their target price on shares of Avalo Therapeutics from $35.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday, August 7th. Mizuho upped their price target on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the stock an "outperform" rating in a report on Thursday, May 14th. Citizens Jmp dropped their price target on Avalo Therapeutics from $62.00 to $55.00 and set a "market outperform" rating for the company in a research note on Thursday, May 14th. Citigroup reissued an "outperform" rating on shares of Avalo Therapeutics in a report on Wednesday, May 6th. Finally, Weiss Ratings upgraded Avalo Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Thirteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $45.10.

Avalo Therapeutics Stock Performance

The business's fifty day moving average is $18.68 and its 200-day moving average is $16.66. The firm has a market cap of $1.12 billion, a P/E ratio of -4.78 and a beta of 0.80.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.25). Analysts predict that Avalo Therapeutics, Inc. will post -2.59 EPS for the current fiscal year.

Insider Buying and Selling at Avalo Therapeutics

In related news, insider Mittie Doyle sold 1,450 shares of the business's stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the sale, the insider owned 51,776 shares of the company's stock, valued at $931,968. The trade was a 2.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.46% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AVTX. Braidwell LP acquired a new stake in shares of Avalo Therapeutics in the second quarter valued at about $30,107,000. Orbimed Advisors LLC lifted its stake in shares of Avalo Therapeutics by 39.5% in the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company's stock worth $17,150,000 after acquiring an additional 382,300 shares during the period. Affinity Asset Advisors LLC lifted its stake in shares of Avalo Therapeutics by 27.6% in the first quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company's stock worth $20,019,000 after acquiring an additional 289,786 shares during the period. Nantahala Capital Management LLC boosted its holdings in Avalo Therapeutics by 24.1% in the third quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company's stock valued at $15,697,000 after acquiring an additional 240,000 shares during the last quarter. Finally, Caligan Partners LP boosted its holdings in Avalo Therapeutics by 5.8% in the fourth quarter. Caligan Partners LP now owns 881,533 shares of the company's stock valued at $16,009,000 after acquiring an additional 48,200 shares during the last quarter. 87.06% of the stock is owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source